Esophageal cancer, characterized by its high mortality rate, remains a major health concern globally. This malignancy primarily manifests in two forms: squamous cell carcinoma and adenocarcinoma. Understanding the cellular and molecular underpinnings of these cancers is essential for developing effective treatment options. The complexity of esophageal cancer further escalates as it often presents at advanced stages, complicating early detection and intervention.

Integral to understanding cancer biology is the ubiquitin-proteasome system (UPS), which is responsible for protein degradation and regulation within the cell. Inhibition or malfunction of this system can lead to the accumulation of oncogenic proteins, fostering tumor growth and survival. In this context, ubiquitin-specific protease 1 (USP1) has emerged as a key player. By deubiquitinating target proteins, USP1 can modulate their stability and activity, making it a molecule of interest in cancer research.

In the study, the authors focus on the role of USP1 in relation to CDC25A, a dual-specificity phosphatase that plays a crucial role in cell cycle regulation. CDC25A functions to activate cyclin-dependent kinases (CDKs), which are essential for the progression through various phases of the cell cycle. The dysregulation of CDC25A is often observed in different cancers, including esophageal cancer, suggesting its involvement in oncogenic processes.

Through experimental validation, the researchers elucidate the function of USP1 in stabilizing CDC25A by removing ubiquitin moieties from it. This is significant, as stabilized CDC25A can, in turn, enhance the expression of CDK1, a cyclin-dependent kinase that drives the transition from the G2 phase to mitosis. The interplay among USP1, CDC25A, and CDK1 creates a feedback loop that significantly influences cell proliferation and tumor growth.

The findings of this research not only enhance our understanding of esophageal cancer but also highlight potential therapeutic targets. By inhibiting USP1, it may be possible to decrease CDC25A levels, leading to reduced CDK1 activity and, consequently, hindered cancer cell proliferation. Such targeted therapeutic strategies could transform the current landscape of esophageal cancer treatment, which is often limited to surgery, chemotherapy, and radiation.

Moreover, the implications of the study extend beyond esophageal cancer. The pathways involving USP1, CDC25A, and CDK1 are conserved across various cancer types, positioning USP1 as a potential pan-cancer target. By further exploring these molecular interactions, researchers could unveil new insights into the treatment of other malignancies that share similar regulatory pathways.

The study by Feng and colleagues is a testament to the importance of molecular biology in elucidating the complexities of cancer. It serves as a reminder that understanding the intricate signaling networks within cells can pave the way for innovative treatment modalities. As the research community continues to unravel the mechanisms driving cancer progression, the promise of targeted therapies becomes ever more attainable.

The authors emphasize that further studies are needed to validate their findings in clinical settings and to evaluate the potential side effects of USP1 inhibition. It is critical to understand whether the therapeutic targeting of USP1 would affect normal cells as well, and if so, how this could be managed in treatment regimens.

As this research gains traction, the interest in identifying and developing USP1 inhibitors could escalate. Pharmaceutical companies may begin to explore compounds that can target USP1 effectively. The challenge will lie in ensuring that such inhibitors are selective, minimizing off-target effects while maximizing therapeutic efficacy.

As we look to the future, the integration of molecular insights from studies like this into clinical applications holds promise for improving patient outcomes in esophageal cancer. With the ongoing advancements in cancer therapeutics and increased understanding of tumor biology, the vision of precision medicine becomes increasingly viable.

Feng, Yan, and Ge’s research not only marks a significant milestone in cancer biology but also ignites hope for patients battling esophageal cancer. By targeting the underlying molecular mechanisms driving tumor progression, we may one day develop effective treatments that significantly improve survival rates and quality of life for those affected by this dire illness.

In conclusion, the intersection of molecular biology and cancer therapy continues to evolve, and the research conducted by Feng and colleagues serves as a crucial contribution to this dynamic field. The work underscores the necessity for ongoing investigation into cancer pathways, with the collective aim of translating these findings into clinical success.

Subject of Research: The regulatory role of USP1 in esophageal cancer, focusing on CDC25A deubiquitination and CDK1 expression.

Article Title: USP1 regulates esophageal cancer progression through CDC25A deubiquitination to regulate CDK1 expression.

Article References: Feng, J., Yan, Z. & Ge, J. USP1 regulates esophageal cancer progression through CDC25A deubiquitination to regulate CDK1 expression. 3 Biotech 16, 47 (2026). https://doi.org/10.1007/s13205-025-04663-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s13205-025-04663-1

Keywords: USP1, esophageal cancer, CDC25A, CDK1, ubiquitin-proteasome system, targeted therapy, cancer biology, molecular mechanisms.

Central to cancer biology is the sonic hedgehog (Shh) signaling pathway, a molecular cascade integral to embryonic development but frequently hijacked by malignancies to facilitate unchecked growth and resistance to apoptosis. Within this pathway, the Gli family of transcription factors—particularly Gli1—serves as master regulators that activate genes promoting proliferation and survival. Overexpression of Gli1 has been implicated in the pathogenesis and aggressiveness of various tumors, including gastric carcinoma. Thus, modulating Gli1 activity presents a promising strategy to undermine tumor viability.

In this context, the research team focused on MKN45 cells, a human gastric cancer cell line emblematic of a particularly aggressive cancer subtype. By administering C-phycocyanin to these cells, the scientists observed a significant downregulation of Gli1 gene expression, pointing to a direct interference with the sonic hedgehog pathway. This disruption implies that C-phycocyanin can effectively blunt the proliferative signals that cancer cells rely upon, paving the way for reduced tumor growth and enhanced sensitivity to apoptosis.

Equally compelling was the observed modulation of the Bcl-2 gene, a pivotal anti-apoptotic gene that endows cancer cells with survival advantages by thwarting programmed cell death. Overexpression of Bcl-2 is a hallmark of many cancers, conferring resistance to chemotherapy and radiotherapy. The study demonstrated that C-phycocyanin markedly decreased Bcl-2 expression in MKN45 cells. This dual targeting of both Gli1 and Bcl-2 signifies a powerful mechanism by which C-phycocyanin undermines not just cellular proliferation but also the intrinsic survival machinery of gastric cancer cells.

The researchers employed quantitative real-time polymerase chain reaction (qRT-PCR) to quantify gene expression changes, ensuring precise measurement of the downregulation effects induced by C-phycocyanin. Such meticulous molecular analysis affirms the robustness of the findings and underscores the compound’s potential as a molecular modulator in oncogenic pathways. Understanding these gene expression shifts is critical for designing future interventions that harness the full therapeutic potential of natural compounds.

Beyond gene expression, the implications of this research extend to therapeutic resistance. Cancer cells frequently adapt to survive in hostile microenvironments and under chemotherapeutic stress by upregulating survival genes like Bcl-2. By suppressing this gene, C-phycocyanin may sensitize gastric cancer cells to conventional treatments, potentially bolstering the efficacy of existing drug regimens and reducing relapse rates—a pivotal consideration in oncological management.

The significance of these findings lies not only in their molecular novelty but also in the translational prospect of C-phycocyanin. Derived from Spirulina, a widely consumed dietary supplement, C-phycocyanin boasts a favorable safety profile, which could accelerate its repositioning as an adjunct anti-cancer agent. Its ability to modulate key signaling pathways selectively and with minimal toxicity heralds a new era of biocompatible therapeutics.

Gastric cancer remains a formidable global health challenge, ranking as one of the leading causes of cancer-related mortality worldwide. Despite advances in surgical and pharmacological interventions, five-year survival rates remain disappointingly low. Molecularly targeted agents that disrupt tumor-promoting pathways without damaging healthy tissues are the cornerstone of modern oncology, and compounds like C-phycocyanin are poised to join this elite cadre of therapeutics.

Importantly, this study bridges a critical gap in understanding how natural bioactive molecules influence the sonic hedgehog signaling axis. While prior research implicated aberrant Shh pathway activity in gastric cancer, pharmacologic inhibitors have been limited by toxicity and specificity issues. The discovery that a natural compound can attenuate Gli1 expression offers a tantalizing alternative with fewer side effects and potentially broader application across tumor types exhibiting Shh pathway dysregulation.

Future investigations will likely expand on these findings by exploring the effects of C-phycocyanin in vivo and assessing possible synergistic effects with chemotherapeutic agents or other pathway inhibitors. Additionally, delineating the precise molecular interactions between C-phycocyanin and the components of the Shh pathway could unfold new mechanistic insights and inform the design of novel drugs inspired by this natural molecule.

This research also adds to the growing body of evidence favoring the integration of nutraceuticals into oncology. As the scientific community increasingly appreciates the multifaceted biological activities of natural compounds, studies like these underscore the necessity of rigorous, molecular-level evaluations to identify candidates suitable for clinical translation.

Moreover, the suppression of Bcl-2 by C-phycocyanin has ramifications beyond gastric cancer. Since Bcl-2 overexpression is common in lymphomas, leukemias, and solid tumors, the findings suggest a wider applicability of C-phycocyanin as a therapeutic agent. This broad-spectrum potential could revolutionize cancer treatment paradigms, emphasizing the synergy between natural product chemistry and molecular oncology.

In sum, the investigation spearheaded by Lotfi, Tabaripour, Ahmadi, and colleagues stands as a pivotal contribution to cancer research. By elucidating how C-phycocyanin targets the sonic hedgehog pathway through Gli1 and impairs cellular survival via Bcl-2 suppression, the study charts a course towards innovative, less toxic interventions in gastric cancer management. The prospect of harnessing this natural compound to disrupt tumorigenic signaling networks invigorates hope for patients and clinicians alike, heralding a new chapter in the war against cancer.

This landmark study not only enriches the molecular understanding of gastric cancer but also paves the way for harnessing natural compounds with potent bioactivity. As precision medicine continues to evolve, targeting genetic and signaling aberrations with agents like C-phycocyanin could become a mainstay, fundamentally altering therapeutic landscapes. The integration of such novel bioactives could drastically improve patient outcomes and quality of life.

The enthusiasm surrounding C-phycocyanin emerges from a confluence of traditional knowledge and rigorous modern science. Its identification as an inhibitor of pivotal oncogenic pathways exemplifies the untapped potential residing in nature’s pharmacopeia. Unlocking this potential requires continued deep molecular investigations and carefully designed clinical trials to validate efficacy and safety in complex human systems.

As the scientific community embraces these findings, there is palpable excitement about the potential to develop C-phycocyanin-based formulations optimized for bioavailability and targeted delivery. Such advancements could enhance its therapeutic index and enable personalized treatment regimens, tailored to the unique genetic and molecular profiles of individual tumors.

Ultimately, this research represents a promising stride forward in the relentless pursuit of more effective cancer therapies. By shining a light on the molecular underpinnings of C-phycocyanin’s anti-cancer effects, the study offers a blueprint for the rational development of novel agents that combine efficacy, safety, and patient tolerability—qualities urgently needed to combat gastric cancer and potentially many other malignancies.

Subject of Research:
The effect of C-phycocyanin on sonic hedgehog pathway-related Gli1 and Bcl-2 gene expression in human gastric cancer cells.

Article Title:
Investigation of the effect of C-phycocyanin on sonic hedgehog pathway-related Gli1 and Bcl-2 gene expression in MKN45 gastric cancer cells.

Article References:
Lotfi, M., Tabaripour, R., Ahmadi, A. et al. Investigation of the effect of C-phycocyanin on sonic hedgehog pathway-related Gli1 and Bcl-2 gene expression in MKN45 gastric cancer cells. Med Oncol 42, 370 (2025). https://doi.org/10.1007/s12032-025-02748-8

Image Credits:
AI Generated